CN1433307A - 用于治疗充血性心力衰竭的前列腺素类化合物 - Google Patents

用于治疗充血性心力衰竭的前列腺素类化合物 Download PDF

Info

Publication number
CN1433307A
CN1433307A CN01810746A CN01810746A CN1433307A CN 1433307 A CN1433307 A CN 1433307A CN 01810746 A CN01810746 A CN 01810746A CN 01810746 A CN01810746 A CN 01810746A CN 1433307 A CN1433307 A CN 1433307A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
group
pharmaceutically acceptable
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01810746A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·肖尔
马蒂纳·罗思布拉特
迈克尔·本特利
赵宣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of CN1433307A publication Critical patent/CN1433307A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN01810746A 2000-06-05 2001-05-03 用于治疗充血性心力衰竭的前列腺素类化合物 Pending CN1433307A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/587,458 2000-06-05
US09/587,458 US6242482B1 (en) 2000-06-05 2000-06-05 Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
CN1433307A true CN1433307A (zh) 2003-07-30

Family

ID=24349885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01810746A Pending CN1433307A (zh) 2000-06-05 2001-05-03 用于治疗充血性心力衰竭的前列腺素类化合物

Country Status (8)

Country Link
US (1) US6242482B1 (fr)
EP (1) EP1299096A1 (fr)
JP (1) JP2003535132A (fr)
KR (1) KR20030038547A (fr)
CN (1) CN1433307A (fr)
AU (1) AU2001257521A1 (fr)
CA (1) CA2408542A1 (fr)
WO (1) WO2001093862A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884093A (zh) * 2012-12-07 2015-09-02 阿森迪斯药物股份有限公司 载体连接型前列腺素类前药
CN108947843A (zh) * 2013-10-25 2018-12-07 英斯梅德股份有限公司 前列环素化合物、其组合物及使用方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ES2622471T5 (es) 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
US20070014784A1 (en) * 2005-06-23 2007-01-18 Medtronic Vascular, Inc. Methods and Systems for Treating Injured Cardiac Tissue
EP2026816B1 (fr) 2006-05-15 2018-10-24 United Therapeutics Corporation Administration de treprostinil utilisant un inhalateur à dose mesurée
US10213464B2 (en) * 2011-01-13 2019-02-26 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
HK1198358A1 (en) * 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
LT2674413T (lt) * 2012-06-15 2017-09-25 Scipharm Sąrl Treprostinilo ir jo darinių gavimo būdas
EP3712142B1 (fr) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Promédicaments de tréprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
JP6561109B2 (ja) * 2014-07-16 2019-08-14 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
MX2021003866A (es) 2018-10-05 2021-09-08 Xenotherapeutics Inc Productos y metodos de xenotransplante.
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
USD1037201S1 (en) * 2022-05-25 2024-07-30 Razer (Asia Pacific) Pte. Ltd. Headphone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2359652A1 (fr) 1999-03-31 2000-10-05 United Therapeutics Corporation Composes de prostaglandine, compositions et methodes de traitement de maladies vasculaires peripheriques et de l'hypertension pulmonaire

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884093A (zh) * 2012-12-07 2015-09-02 阿森迪斯药物股份有限公司 载体连接型前列腺素类前药
CN108947843A (zh) * 2013-10-25 2018-12-07 英斯梅德股份有限公司 前列环素化合物、其组合物及使用方法
US11795135B2 (en) 2013-10-25 2023-10-24 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2408542A1 (fr) 2001-12-13
EP1299096A1 (fr) 2003-04-09
WO2001093862A1 (fr) 2001-12-13
AU2001257521A1 (en) 2001-12-17
KR20030038547A (ko) 2003-05-16
US6242482B1 (en) 2001-06-05
JP2003535132A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
CN1433307A (zh) 用于治疗充血性心力衰竭的前列腺素类化合物
CN1354622A (zh) 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法
CN1313447C (zh) 用于降低眼内压的8－氮杂前列腺素类似物
CN1132632C (zh) 缓释药物组合物
CN1638809A (zh) 低分子量物质与修饰多糖的偶联
CN1520290A (zh) 含铜胺氧化酶的碳环肼基抑制剂
CN1878545A (zh) 甲状腺激素类似物及其使用方法
CN1864675A (zh) 柚皮素及其衍生物用于制备抗心脑系统疾病产品的用途
AU2012290987B2 (en) Left ventricular diastolic function improving agent
CN1897959A (zh) 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
JP2004503464A (ja) 糖尿病および関連する状態を治療するための新規化合物
CN1518447A (zh) 作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
KR100842240B1 (ko) 저알부민혈증 개선제
CN1657529A (zh) 2－取代亚胺噻唑烷衍生物，其制备工艺及药物组合物
CN1700920A (zh) 羟基甾族化合物的预防和治疗应用
CN1108095A (zh) 用于预防和治疗近视的组合物
JP4914344B2 (ja) 虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
MX2011001167A (es) Conjugados peptido-polimero.
JP5547816B2 (ja) タンパク質−ポリマー接合体の治療的使用
JPWO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
CN1499971A (zh) 芳基乙烯磺酰胺衍生物的新用途
WO2001072730A1 (fr) Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe
CN1746168A (zh) 光学活性的多沙唑嗪盐
US20040242485A1 (en) Compositions and methods for the amelioration of leptin resistance
CN1923205A (zh) (－)多沙唑嗪在制备治疗下尿路症状、膀胱过度活动疾病的药物制剂中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication